Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Rockwell Medical Inc. RMTI

Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The company operates in one segment of the hemodialysis market which involves the exports, manufacture, sale, and distribution of hemodialysis products. Key revenue is generated from the United States.


Recent & Breaking News (NDAQ:RMTI)

Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

PR Newswire 11 days ago

Rockwell Medical Provides Corporate and Clinical Update

PR Newswire 13 days ago

Rockwell Medical Closes $15 Million Financing from Leading Healthcare Investor

PR Newswire June 7, 2022

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

PR Newswire June 1, 2022

Rockwell Medical Announces $15 Million At-Market Offering

PR Newswire May 31, 2022

Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference

PR Newswire May 23, 2022

Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

PR Newswire May 16, 2022

Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

PR Newswire May 12, 2022

Rockwell Medical Announces 1-for-11 Reverse Stock Split

PR Newswire May 12, 2022

Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

PR Newswire May 11, 2022

Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China

PR Newswire April 25, 2022

Rockwell Medical to Present at Noblecon18 Investor Conference

PR Newswire April 20, 2022

Rockwell Medical Expands Partnership with DaVita

PR Newswire April 11, 2022

New Survey from Rockwell Medical Reveals Management of Iron Deficiency Anemia in Home Infusion Patients Does Not Adequately Address Medical Need

PR Newswire March 15, 2022

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association's 2022 Annual Conference

GlobeNewswire March 9, 2022

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

GlobeNewswire February 15, 2022

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 14, 2022

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea

GlobeNewswire January 20, 2022

The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

Accesswire January 14, 2022

Rockwell Medical (NSD:RMTI) announces regulatory approval of Triferic® AVNU in South Korea

John Ballem  January 14, 2022